Role of the lysozyme inhibitor Ivy in growth or survival of Escherichia coli and Pseudomonas aeruginosa bacteria in hen egg white and in human saliva and breast milk

Applied and Environmental Microbiology

Volumn 74, Issue 14, 2008, Pages 4434-4439

  Deckers, Daphne ^a   Vanlint, Dietrich ^a   Callewaert, Lien ^a   Aertsen, Abram ^a   Michiels, Chris W ^a,b  

^a LEUVEN FOOD SCIENCE AND NUTRITION RESEARCH CENTRE LFORCE   (Belgium)

^b Laboratory of Food Microbiology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL CULTURE; BODY FLUIDS; CELL MEMBRANES; ENZYMES; FOOD PRODUCTS PLANTS; WATER POLLUTION;

BREAST MILK; CELL WALLS; E. COLI; EGG WHITE; HEN EGG; HUMAN SALIVA; LYSOZYME (LSZ); LYSOZYME INHIBITOR; OUTER MEMBRANES; PHYSICAL STRESS; PSEUDOMONAS AERUGINOSA (APRIN); PSEUDOMONAS AERUGINOSA BACTERIA; WILD-TYPE (WT);

ESCHERICHIA COLI;

LYSOZYME;

BACTERIUM; COLONIZATION; ENZYME ACTIVITY; GROWTH RATE; HYDROLYSIS; INHIBITOR; MILK; MUTATION; POULTRY; SALIVA; SURVIVAL;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BREAST MILK; CONTROLLED STUDY; ESCHERICHIA COLI; HEN; HUMAN; IVY; NONHUMAN; PROTEIN DEPLETION; PSEUDOMONAS AERUGINOSA; SALIVA; WILD TYPE;

ANIMALS; CARRIER PROTEINS; CHICKENS; COLONY COUNT, MICROBIAL; EGG WHITE; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GENE SILENCING; HUMANS; MICROBIAL VIABILITY; MILK, HUMAN; MURAMIDASE; PSEUDOMONAS AERUGINOSA; SALIVA;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; HEDERA; PSEUDOMONAS AERUGINOSA;

EID: 47749136690     PISSN: 00992240     EISSN: None     Source Type: Journal    
DOI: 10.1128/AEM.00589-08     Document Type: Article

References (38)

1. Abergel, C., V. Monchois, D. Byrbe, S. Chenivesse, F. Lembo, J.-C. Lazzaroni, and J.-M. Claverie. 2007. Structure and evolution of the Ivy protein family, unexpected lysozyme inhibitors in Gram-negative bacteria. Proc. Natl. Acad. Sci. USA 104:6394-6399.
2. Bals, R., X. Wang, Z. Wu, T. Freemann, V. Bafna, M. Zasloff, and J. M. Wilson. 1998. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J. Clin. Investig. 102:874-880.
3. Bals, R., X. Wang, M. Zasloff, and J. M. Wilson. 1998. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl. Acad. Sci. USA 95:9541-9546.
4. Bera, A., S. Herbert, A. Jakob, W. Vollmer, and F. Götz. 2005. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol. Microbiol. 55:778-787.
5. Callewaert, L., A. Aertsen, D. Deckers, K. G. A. Vanoirbeek, L. Vanderkelen, J. M. Van Herreweghe, B. Masschalck, D. Nakimbugwe, J. Robben, and C. W. Michiels. 2008. A new family of lysozyme inhibitors contributing to lysozyme tolerance in gram-negative bacteria. PLoS Pathog. 4:e1000019.
6. Callewaert, L., B. Masschalck, D. Deckers, D. Nakimbugwe, M. Atanassova, B. Aertsen, and C. W. Michiels. 2005. Purification of Ivy, a lysozyme inhibitor from Escherichia coli, and characterisation of its specificity for various lysozymes. Enzyme Microb. Technol. 37:205-211.
7. Cardenosa Cendrero, J. A., J. Sole-Violoan, A. B. Benitez, J. N. Catalán, J. A. Fernández, P. S. Santana, and F. Rodríguez de Castro. 1999. Role of different routes of tracheal colonization in the development of pneumonia in patients receiving mechanical ventilation. Chest 116:462-470.
8. Chierici, R., S. Fanaro, D. Saccomandi, and V. Vigi. 2003. Advances in the modulation of microbial ecology of the gut in early infancy. Acta Paediatr. Suppl. 91:56-63.
9. Clarke, A., and C. Dupont. 1992. O-acetylated peptidoglycan: its occurrence, pathobiological significance, and biosynthesis. Can. J. Microbiol. 38:85-91.
10. Coutinho, P. M., and B. Henrissat. 1999. Carbohydrate-active enzymes: an integrated database approach, p. 3-12. In H. J. Gilbert, G. Davies, B. Henrissat, and B. Svensson (ed.), Recent advances in carbohydrate bioengineering. The Royal Society of Chemistry, Cambridge, United Kingdom.
11. Deckers, D., B. Masschalck, A. Aertsen, L. Callewaert, C. G. M. Van Tiggelen, M. Atanassova, and C. W. Michiels. 2004. Periplasmic lysozyme inhibitor contributes to lysozyme resistance in Escherichia coli. Cell. Mol. Life Sci. 61:1229-1237.
12. de Jonge, E., M. J. Schultz, L. Spanjaard, P. M. M. Bossuyt, M. B. Vroom, J. Dankert, and J. Kesecioglu. 2003. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 362:1011-1016.
13. Ellison, R. T., III, and T. J. Giehl. 1991. Killing of gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Investig. 88:1080-1091.
14. 2+. J. Gen. Microbiol. 136:1437-1446.
15. Franken, C., C. J. M. Meijer, and J. H. Dijkman. 1989. Tissue distribution of antileukoprotease and lysozyme in humans. J. Histochem. Cytochem. 37:493-498.
16. Ganz, T., and J. Weiss. 1997. Antimicrobial peptides of phagocytes and epithelia. Semin. Hematol. 34:343-354.
17. Garcia, R. 2005. A review of the possible role of oral and dental colonization on the occurrence of health care-associated pneumonia: underappreciated risk and a call for interventions. Am. J. Infect. Control 33:527-541.
18. Gaynes, R., J. R. Edwards, and National Nosocomial Infections Surveillance System. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
19. Germaine, G. R., and L. M. Tellefson. 1979. Simple and rapid procedure for the selective removal of lysozyme from human saliva. Infect. Immun. 26:991-995.
20. Grossowicz, N., and M. Ariel. 1983. Methods for determination of lysozyme activity. Methods Biochem. Anal. 29:435-446.
21. Ibrahim, H. R., D. Inazaki, A. Abdou, T. Aoki, and M. Kim. 2005. Processing of lysozyme at distinct loops by pepsin: a novel action for generating multiple antimicrobial peptide motifs in the newborn stomach. Biochim. Biophys. Acta 1726:102-114.
22. Ibrahim, H. R., Y. Sugimoto, and T. Aoki. 2000. Ovotransferrin antimicrobial peptide (OTAP-92) kills bacteria through a membrane damage mechanism. Biochim. Biophys. Acta 1523:196-205.
23. Johanson, W. G., A. K. Pierce, and J. P. Sanford. 1969. Changing pharyngeal bacterial flora of hospitalized patients. Emergence of gram-negative bacilli. N. Engl. J. Med. 281:1137-1140.
24. Laemmli, M. 1970. Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature 227:680-685.
25. Leibovitz, A., M. Dan, J. Zinger, Y. Carmeli, B. Habot, and R. Segal. 2003. Pseudomonas aeruginosa and the oropharyngeal ecosystem of tube-fed patients. Emerg. Infect. Dis. 9:956-959.
26. Lewenza, S., R. K. Falsafi, G. Winsor, W. J. Gooderham, J. B. McPhee, F. S. Brinkman, and R. E. W. Hancock. 2005. Construction of a mini-Tn5-luxC-DABE mutant library in Pseudomonas aeruginosa PAO1: a tool for identifying differentially regulated genes. Genome Res. 15:583-589.
27. Lovelady, C. A., C. P. Hunter, and C. Geigerman. 2003. Effect of exercise on immunologic factors in breast milk. Pediatrics 111:148-152.
28. Maga, A. E., R. L. Walker, G. B. Anderson, and J. D. Murray. 2006. Consumption of milk from transgenic goats expressing human lysozyme in the mammary gland results in the modulation of intestinal microflora. Transgenic Res. 15:515-519.
29. Mason, D. Y., and C. R. Taylor. 1975. The distribution of muramidase (lysozyme) in human tissues. J. Clin. Pathol. 28:124-132.
30. Monchois, V., C. Aberel, J. Sturgis, S. Jeudy, and J. M. Claverie. 2001. Escherichia coli ykfE ORFan gene encodes a potent inhibitor of C-type lysozyme. J. Biol. Chem. 276:18437-18441.
31. Rogan, M. P., P. Geraghty, C. M. Greene, S. J. O'Neill, C. C. Taggart, and N. G. McElvaney. 2006. Antimicrobial proteins and polypeptides in pulmonary innate defence. Respir. Res. 7:29-39.
32. Senpuku, H., A. Sogame, E. Inoshita, Y. Tsuha, H. Miyazaki, and N. Hanada. 2003. Systemic diseases in association with microbial species in oral biofilm from elderly requiring care. Gerontology 49:301-309.
33. Shelburne, S. A., III, C. Ganville, M. Tokuyama, I. Sitkiewics, P. Patel, and J. M. Musser. 2005. Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva. Infect. Immun. 73:4723-4731.
34. Taylor, P. W. 1983. Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol. Rev. 47:46-83.
35. Vollmer, W., and A. Tomasz. 2002. Peptidoglycan N-acetylglucosamine deacetylase, a putative virulence factor in Streptococcus pneumoniae. Infect. Immun. 70:7176-7178.
36. Vollmer, W., and A. Tomasz. 2000. The pgdA gene encodes for a peptidoglycan N-acetylglucosamine deacetylase in Streptococcus pneumoniae. J. Biol. Chem. 275:20496-20501.
37. Wehkamp, J., H. Chu, B. Shen, R. W. Feathers, R. J. Kays, S. K. Lee, and C. L. Bevins. 2006. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett. 580:5344-5350.
38. Zipperle, G. F., J. W. Ezzell, and R. J. Doyle. 1984. Glucosamine substitution and muramidase susceptibility in Bacillus anthracis. Can. J. Microbiol. 30:553-559.